Evidence map›Paper›PMID 42266928›Full record

ArticleFrontiers in cellular and infection microbiology2026

Clinical risk factors and genomic characterization of carbapenem-resistant

Wenxia Zhang, Shufen Liu, Boyu Yang, Xiuhua Hu, Minlan Zhang, Xinghua Zhou, Jinrong Guo, Min He, Fenghua Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenxia Zhang *Department of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.
Shufen Liu *Department of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.
Boyu YangDepartment of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.
Xiuhua HuDepartment of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.
Minlan ZhangDepartment of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.
Xinghua ZhouDepartment of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.
Jinrong GuoDepartment of Traditional Chinese Medicine, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
Min HeClinical Research Center, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Fenghua ZhangDepartment of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbapenem-resistant Methods: We conducted a retrospective study of patients with microbiologically confirmed CRKP infections at a tertiary TCM hospital between 2019 and 2022. Multivariate logistic regression was used to assess independent risk factors for mortality. We performed whole-genome sequencing on 102 CRKP isolates (2022) to characterize antimicrobial resistance determinants, virulence factors, and phylogenetic relationships. Results: In our cohort of 233 CRKP-infected patients (76 non-survivors, 157 survivors), multivariate analysis identified four independent predictors of in-hospital mortality: multiple organ dysfunction syndrome (aOR 3.69, 95% CI 1.28-10.61; P = 0.015), sepsis (aOR 3.04, 95% CI 1.30-7.12; P = 0.011), invasive mechanical ventilation (aOR 5.95, 95% CI 2.78-12.75; P<0.001), and ICU admission (aOR 4.10, 95% CI 1.55-10.84; P = 0.005). Genomic analysis identified ST11-KL64 (55.9%, 57/102) and ST15-KL19 (21.6%, 22/102) as dominant clones, alongside novel strains ST1658-KL60 and ST3345-KL8. The prevalent plasmid was IncFIB(K) (85.3%), followed by IncHI1B (66.7%); IncFII(pHN7A8) (28.4%) was exclusive to ST11. The predominant capsular type was KL64:O2a. Carbapenem resistance was primarily driven by Conclusions: Our study highlights the predominance of ST11-KL64 and ST15-KL19 CRKP clones in a TCM hospital setting, with

Indexed as

Carbapenem-Resistant EnterobacteriaceaeCarbapenemsKlebsiella InfectionsKlebsiella pneumoniaeAgedAnti-Bacterial Agentsbeta-LactamasesChinaCross InfectionDrug Resistance, Multiple, BacterialFemaleHospital MortalityHumansMaleMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial Agentsbeta-LactamasesCarbapenemsVirulence FactorsblaKPC-2 variantKlebsiella pneumoniaemortality risk factorsvirulence factorswhole genome sequencing

Identifiers

PMID42266928
PMCPMC13243436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.